Claims for Patent: 5,984,906
✉ Email this page to a colleague
Summary for Patent: 5,984,906
| Title: | Syringe system |
| Abstract: | An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G 30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 .mu.m. |
| Inventor(s): | Bonnichsen; Frits Frydendal (Lynge, DK), J.o slashed.rgensen; Peter Nissen (Broenshoej, DK) |
| Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
| Application Number: | 08/794,026 |
| Patent Claims: | 1. An insulin injection system comprising a pen shaped syringe comprising a cartridge with insulin and an injection needle, wherein the needle is thinner than a G-29 needle and the
cartridge contains an insulin type which may freely flow through a needle thinner than a G-29 needle.
2. An insulin injection system according the claim 1, wherein the insulin type in the cartridge has a maximal crystals size of 15 .mu.m. 3. An insulin injection system according to claim 1, wherein the pen shaped syringe is a disposable device prefilled with insulin. 4. An insulin injection system according to claim 1, wherein the pen shaped syringe is a durable device designed to receive only cartridges containing insulin which may pass freely through a thinner than G-29 needle. 5. An insulin injection system according to claim 1, wherein the needle has attaching means for cooperation with attaching means on the pen shaped syringe. 6. An insulin injection system according to claim 5, wherein the needle attaching means is a needle hub having a thread cooperating with a corresponding thread on the pen shaped syringe. 7. An insulin injection system according to claim 6, wherein the needle hub has a central protrusion covering part of the length of the needle. 8. An insulin injection system according to claim 7, wherein the length of the injection part of the needle is 8-12 mm. 9. An insulin injection system according to claim 2, wherein the pen shaped syringe is a disposable device prefilled with insulin. 10. An insulin injection system according to claim 2, wherein the pen shaped syringe is a durable device designed to receive only cartridges containing insulin which may pass freely through a thinner than G-29 needle. 11. A needle assembly comprising: (a) a needle hub having a base and a standard insulin needle fitting for removably mounting said needle assembly on a pen-type insulin syringe having a standard mounting and which accepts cartridges containing only insulin types that may flow freely through a thinner than G-29 needle; and (b) a thinner than G-29 needle secured in said base and having first and second needle portions extending from said base in opposite directions. 12. A needle assembly according to claim 11, wherein said standard fitting includes an annular sleeve extending from said base such that said sleeve surrounds said first needle portion concentrically and is spaced therefrom, and wherein said sleeve has a threaded interior by which it may be screwed onto a standard, externally threaded, hub-receiving part of a pen-type insulin syringe. 13. A needle assembly according to claim 12, and wherein said second needle portion has a predetermined length appropriate for injecting insulin into a human patient. 14. A needle assembly according to claim 13, wherein said base further comprises a central protrusion which extends from said base for a predetermined distance along said second needle portion and embeds said second needle portion along the said distance, and wherein said second needle portion further comprises an exposed end which projects axially from said central protrusion and which has a length corresponding to the desired depth of needle insertion into a human patient. |
Details for Patent 5,984,906
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | October 28, 1982 | 5,984,906 | 2017-02-03 |
| Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | December 29, 2015 | 5,984,906 | 2017-02-03 |
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | August 06, 1998 | 5,984,906 | 2017-02-03 |
| Eli Lilly And Company | HUMULIN R U-500 | insulin human | Injection | 018780 | March 31, 1994 | 5,984,906 | 2017-02-03 |
| Eli Lilly And Company | HUMULIN R U-100 | insulin human | Injection | 018780 | May 25, 2018 | 5,984,906 | 2017-02-03 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
